

ABOUT TECHNOLOGY CATALYSTS

Our research staff is comprised of professionals with backgrounds in a variety of technical disciplines, with additional expertise in international marketing, licensing, finance and business development. They are skilled in providing clients with strategically important competitive information worldwide. The breadth of our experience assures clients of high quality, actionable information, and complete coverage on topics of interest.

TCI's core consulting services are based on continuous monitoring of technological product development activities on a global basis. The company provides consulting and technology transfer services to leading product developers and manufacturers in North and South America, Europe, and Asia. Our client base consists of small, medium, and large corporations.

For more information on our services and capabilities, please visit us on the internet at:

www.technology-catalysts.com



World Headquarters

Jared Hahn
Manager
Drug Delivery/Pharmaceuticals
605 Park Avenue
Falls Church, VA 22046 U.S.A.
Direct Phone: (703) 531-0254
Facsimile: (703) 237-0042
E-mail: jhahn@
technology-catalysts.com

South America

Carlos A. Massone, M.D.
President
Qualia S.A.
Jeronimo Salguero 2533, Piso 12 "A"
1425-BuenosAires, Argentina
Telephone: 541148073433
Facsimile: 541148072933
Email: carlos.massone@qualia.com.ar

Europe

Graham L. Crawford, MSc
Technology Catalysts International UK
Blacksmiths
Clifton Road
Newton Blossomville
Bedford MK43 8ASU.K.
Telephone: 44 1234 881583
Facsimile: 44 1234 881027
Email: gcrawford@technology-catalysts.com

Ms. Jana Kuhnlova
Executive Managing Director
INVENTIA s.r.o.
Politických veznu 7
110 00 Praha 1, Czech Republic
Telephone: 4202 2224-7484
Facsimile: 4202 242 18645
Email: kuhnlova@inventia.cz
Internet: www.inventia.cz
Dr. Gerhard Wallenwein
Managing Director
Laves Chemie Consulting
Koenigsteiner Strasse 80
D-65812 Bad Soden, Germany
Telephone: 49 (06196) 62057
Facsimile: 49 (06196) 27837
Email: laveschemie@t-online.de
Internet: www.laveschemie.de

Asia

Ken-ichi Itoh
President
TCI Japan
2-46-4, Utsukushigaoka
Aoba-ku, Yokohama 225-0002 Japan
Telephone: 81 45 902 5304
Facsimile: 81 45 902 5476
Email: kenitoh@ca.mbn.or.jp

WOMEN'S HEALTH

Trends, Breakthroughs,

Market Analysis, and

Business Opportunities

in the Pharmacological Treatment

of Non-malignant Conditions

S E C O N D E D I T I O N

WOMEN'S HEALTH

S E C O N D E D I T I O N

TABLE OF CONTENTS

Executive Summary

Introduction

Trends, Breakthroughs, and Market Forecasts

- Breast disease
 - Breast Cancer
 - Prevention
 - Fibrocystic Breast Disease
- Contraception
 - Ovulation Inhibition
 - Endometrium Disruption
 - Sperm Function Inhibitors
- Endometriosis
- Infertility
- Leiomyomata (Uterine Fibroids)
- Menopausal Syndrome/Hormone Replacement Therapy (HRT)
- Menstrual Dysfunction
 - Dysmenorrhea
 - Amenorrhea
 - Premenstrual Syndromes
- Osteoporosis
- Polycystic Ovarian Syndrome (PCOS)

- Pregnancy and Labor
 - Premature Labor
 - Labor Induction
 - Pregnancy-Induced Hypertension
- Sexual Dysfunction
 - Libido Dysfunction
 - Arousal Dysfunction
- Sexually Transmitted Diseases/Cervical Dysplasia
 - Antimicrobials and Immunomodulators
 - Cervical Dysplasia
 - Vaccines
- Urinary System
 - Urinary Tract Infection
 - Urinary Incontinence
- Vaginal Infection
 - Bacterial Vaginosis
 - Vulvo-vaginal Candidiasis

Business Opportunities

INTRODUCTION

A new generation of drugs and therapies will soon revolutionize the way we treat women's health conditions. These advances in pharmacology and drug delivery will soon create large new markets in areas of unmet need for conditions such as:

- Breast diseases
 - Contraception
 - Endometriosis
 - Menopause
 - Osteoporosis
 - Polycystic Ovarian Syndrome
 - Premature Labor
 - Genital Infection / STDs
 - Urinary Incontinence
 - Uterine Fibroids
- The Women's Healthcare Report details market forecasts supporting realistic earnings projections for these new drugs to exceed \$50 billion dollars annually in the next five to ten years.

Technology Catalysts International (TCI) has conducted a global analysis of advanced products and developments in the field of women's health. We have identified 162 drugs or products in 14 therapeutic categories in the research and development pipelines of dozens of companies. We have identified 32 products from 27 companies that are currently available for license or collaboration. These 32 products have been critically evaluated for their competitive advantages and disadvantages so informed decisions can be made as to their attractiveness to potential collaborators.

In addition to identifying trends and business opportunities, a unique feature of this report is an analysis of potential earnings of new drugs. Market forecasts are often presented with a dollar value or range, but the logic and assumptions behind these numbers are not revealed. This report analyzes the interactions of variables such as population dynamics, competition between current and future drugs, and patient and physician biases (from a clinical insider's point of view). These forecasts also identify variables that cannot be ascertained from current information. This information should be extremely valuable to decision makers who want to see the future of their company within the "big picture" of these markets. The information contained in this report should allow individual companies to tailor earnings projections given their current market presence, sales force, R&D pipeline, and financial reserves for direct-to-consumer and physician advertising.

PURCHASE AGREEMENT

- Women's Health, Second Edition (one copy) \$ 2,950
- Each additional copy \$ 300

Note: All prices are U.S. dollars

We agree to limit the circulation of any of these reports to employees of our corporation or subsidiaries and joint ventures in which our corporation holds at least a 50 percent interest.

Upon receipt of this signed Purchase Agreement, Technology Catalysts International will invoice our corporation for the purchase amount, payable upon request.

Name: _____

Title: _____

Company: _____

Address: _____

Telephone: _____

Facsimile: _____

Signature: _____

Date: _____

- Check enclosed, made payable to Technology Catalysts International
- Bill me at this address
- Please send brochure describing the services of Technology Catalysts International
- Please have a representative visit at no cost

Return to:

Jared Hahn

Manager

Drug Delivery/Pharmaceuticals

605 Park Avenue

Falls Church, VA 22046 U.S.A.

Direct Phone: (703) 531-0254

Facsimili: (703) 237-0042

E-mail: jhahn@technology-catalysts.com

Internet: www.technology-catalysts.com